Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-08-19FDA Approved: ACETAZOLAMIDE — Original Application (Advagen Pharma Ltd)
FDA approved Advagen Pharma Ltd's generic acetazolamide under an original (ANDA) application, enabling marketing of a generic formulation of…
-
CLINICAL_TRIALS trial_result · 2021-08-10Clinical Trial Update: Staccato Alprazolam and Photoparoxysmal Response [Phase 2]
Phase 2 clinical trial update for Staccato Alprazolam in epilepsy examining photoparoxysmal response; the study has completed and results ha…
-
CLINICAL_TRIALS trial_result · 2021-08-05Clinical Trial Update: Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy [Phase 3]
Phase 3 trial update on safety and tolerability of diazepam buccal film in epilepsy patients; results posted.
-
CLINICAL_TRIALS research · 2021-08-02Clinical Trial Update: Role of Clinical Pharmacists in Epilepsy Management [Phase 4]
A Phase 4 clinical trial evaluating the role of clinical pharmacists in epilepsy management has completed.
-
FDA approval · 2021-07-13FDA Approved: LEVETIRACETAM — Supplemental Application (Sagent Pharmaceuticals)
The FDA approved a supplemental application for levetiracetam submitted by Sagent Pharmaceuticals.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2021-06-30FDA Approved: TOPAMAX — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for TOPAMAX (topiramate) submitted by Janssen Pharmaceuticals; the snippet does not specify the exac…
-
FDA approval · 2021-06-29FDA Approved: ESLICARBAZEPINE ACETATE — Original Application (Dr.Reddys Laboratories Inc)
FDA approved a generic eslicarbazepine acetate through an Original Application for Dr. Reddy's Laboratories, providing a generic option for …
-
CLINICAL_TRIALS trial_result · 2021-06-22Clinical Trial Update: AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy [Phase 2]
Phase 2 trial AMO-01 for Phelan-McDermid Syndrome with epilepsy has completed and posted results.
-
FDA approval · 2021-06-21FDA Approved: OXCARBAZEPINE — Original Application (Chartwell RX, LLC)
FDA approves Chartwell RX, LLC's original generic oxcarbazepine for treatment of partial seizures in adults and children with epilepsy.
-
FDA approval · 2021-06-11FDA Approved: LEVETIRACETAM — Original Application (ScieGen Pharmaceuticals, Inc.)
FDA approved the original application (ANDA) for LEVETIRACETAM by ScieGen Pharmaceuticals, authorizing the generic product.
-
FDA approval · 2021-06-08FDA Approved: LEVETIRACETAM — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved Torrent Pharmaceuticals Limited's supplemental application for levetiracetam (generic).
-
CLINICAL_TRIALS trial_result · 2021-05-26Clinical Trial Update: Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy [Phase 2]
Phase 2 pharmacokinetics and safety study of Diazepam Buccal Film in pediatric epilepsy patients completed; results posted.
-
CLINICAL_TRIALS withdrawal · 2021-05-21Clinical Trial Update: Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus [Phase 2, Phase 3]
Clinical trial investigating ketamine infusion vs traditional anti-epileptic agents in refractory status epilepticus was withdrawn from phas…
-
FDA approval · 2021-05-17FDA Approved: DIAZEPAM — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for diazepam filed by Hikma Pharmaceuticals USA Inc., marking regulatory clearance for an additi…
-
CLINICAL_TRIALS trial_result · 2021-05-17Clinical Trial Update: A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy [Phase 3]
This Phase 3 trial update reports on the safety of topiramate and levetiracetam for children newly diagnosed with epilepsy.
-
FDA approval · 2021-05-11FDA Approved: RUFINAMIDE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' generic Rufinamide (ANDA 204993) for the treatment of seizures associated with Lennox-Gastaut syndrome,…
-
CLINICAL_TRIALS trial_result · 2021-04-30Clinical Trial Update: Generating Evidence on NonEpileptic, Stereotypical and Intermittent Symptoms (NESIS) in Chronic Subdural Hematomas [Phase 4]
Phase 4 trial update investigating NESIS in chronic subdural hematoma with associated epilepsy/seizure symptoms; current status is unknown.
-
CLINICAL_TRIALS trial_result · 2021-04-27Clinical Trial Update: Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy [Phase 2]
Phase 2 trial investigating natalizumab for focal epilepsy has completed with posted results.
-
FDA approval · 2021-04-26FDA Approved: GABAPENTIN — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Gabapentin from Actavis Pharma, Inc., enabling the generic product to reach the market.
-
FDA approval · 2021-04-23FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for divalproex sodium from Aurobindo Pharma Limited, a generic formulation.
-
CLINICAL_TRIALS trial_result · 2021-04-20Clinical Trial Update: A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II) [Phase 2]
Phase 2 trial investigating everolimus for refractory seizures in focal cortical dysplasia type II has completed.
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization [Phase 3]
Phase 3 trial evaluating intravenous brivaracetam as a replacement for oral brivaracetam in Japanese patients aged 16 and older with partial…
-
FDA approval · 2021-04-13FDA Approved: CARBAMAZEPINE — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved Upsher-Smith Laboratories' Original Application for carbamazepine (generic) under ANDA213311.
-
FDA approval · 2021-04-05FDA Approved: LEVETIRACETAM — Supplemental Application (Hisun Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for LEVETIRACETAM from Hisun Pharmaceuticals USA, Inc., resulting in approval of a generic version o…
-
FDA approval · 2021-03-31FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for LAMICTAL ODT (lamotrigine) submitted by GlaxoSmithKline, updating its regulatory status for …